Imperial College London
Portrait Picture

Professor Martin Wilkins

Faculty of Medicine, National Heart & Lung Institute

Professor of Clinical Pharmacology
 
 
 
//

Contact

 

+44 (0)20 3313 6101m.wilkins Website

 
 
//

Assistant

 

Mrs Elizabeth O'Brien +44 (0)20 3313 6101

 
//

Location

 

NIHR Imperial Clinical Research FacilityICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Ghofrani:2016:10.1016/j.chest.2016.05.024,
author = {Ghofrani, HA and Humbert, M and Langleben, D and Schermuly, R and Stasch, JP and Wilkins, MR and Klinger, JR},
doi = {10.1016/j.chest.2016.05.024},
journal = {Chest},
pages = {468--480},
title = {Riociguat: Mode of action and clinical development in pulmonary hypertension},
url = {http://dx.doi.org/10.1016/j.chest.2016.05.024},
volume = {151},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive and debilitating diseases characterized by gradual obstruction of the pulmonary vasculature, leading to elevated pulmonary artery pressure and increased pulmonary vascular resistance. If untreated, they can result in death due to right heart failure. Riociguat is a novel soluble guanylate cyclase (sGC) stimulator that is approved for the treatment of PAH and CTEPH. Here we describe in detail the role of the nitric oxide-sGC-cyclic guanosine monophosphate (cGMP) signaling pathway in the pathogenesis of PAH and CTEPH, and the mode of action of riociguat. We also review the preclinical data associated with the development of riociguat, along with the efficacy and safety data of riociguat from initial clinical trials and the pivotal Phase III randomized clinical trials in PAH and CTEPH.
AU  - Ghofrani,HA
AU  - Humbert,M
AU  - Langleben,D
AU  - Schermuly,R
AU  - Stasch,JP
AU  - Wilkins,MR
AU  - Klinger,JR
DO  - 10.1016/j.chest.2016.05.024
EP  - 480
PY  - 2016///
SN  - 0012-3692
SP  - 468
TI  - Riociguat: Mode of action and clinical development in pulmonary hypertension
T2  - Chest
UR  - http://dx.doi.org/10.1016/j.chest.2016.05.024
UR  - http://hdl.handle.net/10044/1/38616
VL  - 151
ER  -
Download